Loading
GB
Guizhou Bailing Group Pharmaceutical Co., Ltd. Stock: price and insider trades · China
ST百灵
Guizhou Bailing Group Pharmaceutical Co., Ltd.: what insiders have been doing
Guizhou Bailing Group Pharmaceutical Co., Ltd. has a thin disclosure history in our data (latest filing: 7 June 2021). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€36M
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,975 of 23,476 companies
33.3
score / 100
Value37
Quality30
FCF yld9.8%
Earn yld-1.6%
EV/EBITDA45.1x
ROE-3.9%
Gross mgn47%
Net mgn-3.4%
Debt/EBITDA7.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥4.60
Analyst consensus
Income statement
RevenueCN¥3B
Gross profitCN¥1.4B47% margin
EBITDACN¥168.4M6% margin
Net income-CN¥104.4M-4.9% margin
Valuation
P/Book2.0x
Beta0.24
Balance sheet & cash
Market capCN¥6.4B
Total debtCN¥1.2B
Free Cash FlowCN¥623.5M
Debt / Equity33%
Profitability & ownership
ROE-3.9%
ROA0.5%
% insiders33.2%
% institutions0.5%
Last declaration on 7 June 2021
About Guizhou Bailing Group Pharmaceutical Co., Ltd.
ST百灵 is a company in the health and pharmaceutical sector, listed on the XSHE market. It specializes in the development and manufacturing of pharmaceutical products.
